Screener
Avalo Therapeutics AVTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's retained earnings?
- Avalo Therapeutics (AVTX) reported retained earnings of -$504.51M in Q2 2026.
- How has Avalo Therapeutics's retained earnings changed year-over-year?
- Avalo Therapeutics's retained earnings decreased by 24.8% year-over-year, from -$404.18M to -$504.51M.
- What is the long-term trend for Avalo Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Avalo Therapeutics's retained earnings has grown at a 20.3% compound annual growth rate (CAGR), from -$177.79M to -$448.52M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Avalo Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude